Clinico-morphological features of braf inhibition-induced proliferative skin lesions in cancer patients

Cancer

Volumn 121, Issue 1, 2015, Pages 60-68

  Belum, Viswanath Reddy ^a   Rosen, Alyx C ^a   Jaimes, Natalia ^b   Dranitsaris, George ^c   Pulitzer, Melissa P ^a   Busam, Klaus J ^a   Marghoob, Ashfaq A ^a   Carvajal, Richard D ^a   Chapman, Paul B ^a   Lacouture, Mario E ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSIDAD PONTIFICIA BOLIVARIANA   (Colombia)

^c Augmentium Pharma Consulting   (Canada)

Author keywords

BRAF; Dabrafenib; Keratoacanthoma; Risk factors; Skin neoplasms; Squamous cell carcinoma; Vemurafenib; Verrucous lesion; XL281

Indexed keywords

B RAF KINASE INHIBITOR; DABRAFENIB; KERATIN; VEMURAFENIB; XL 281; BENZIMIDAZOLE DERIVATIVE; CARBAMIC ACID DERIVATIVE; IMIDAZOLE DERIVATIVE; INDOLE DERIVATIVE; OXIME; PROTEIN KINASE INHIBITOR; SULFONAMIDE;

ADULT; AGED; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONFERENCE PAPER; CROSS-SECTIONAL STUDY; EPILUMINESCENCE MICROSCOPY; ERYTHEMA; FEMALE; HISTOPATHOLOGY; HUMAN; KERATOACANTHOMA; MALE; MELANOMA; PAPULE; RISK ASSESSMENT; SKIN BIOPSY; SKIN CARCINOMA; SKIN DEFECT; SKIN NODULE; SKIN ULCER; TUMOR VOLUME; VERRUCOUS CARCINOMA; VERY ELDERLY; CHEMICALLY INDUCED; COMPLICATION; MIDDLE AGED; NEOPLASMS; PATHOLOGY; SKIN DISEASE;

ADULT; AGED; BENZIMIDAZOLES; CARBAMATES; FEMALE; HUMANS; IMIDAZOLES; INDOLES; MALE; MIDDLE AGED; NEOPLASMS; OXIMES; PROTEIN KINASE INHIBITORS; SKIN DISEASES; SULFONAMIDES;

EID: 84919329942     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28980     Document Type: Conference Paper

References (23)

1. Ribas A, Flaherty KT. BRAF targeted therapy changes the treatment paradigm in melanoma. Nat Rev Clin Oncol. 2011;8:426-433.
2. Food and Drug Administration. Highlights of prescribing information for Zelboraf (vemurafenib). http://www.accessdata.fda.gov/drug-satfda-docs/label/2014/202429s005lbl.pdf. Accessed February 16, 2014.
3. McArthur GA, Chapman PB, Robert C, et al. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol. 2014;15:323-332.
4. Food and Drug Administration. Highlights of prescribing information for Tafinlar (dabrafenib). http://www.accessdata.fda.gov/drug-satfda-docs/label/2014/202806s002lbl.pdf. Accessed February 16, 2014.
5. Huang T, Karsy M, Zhuge J, Zhong M, Liu D. B-Raf and the inhibitors: from bench to bedside. J Hematol Oncol. 2013;6:30.
6. Belum VR, Fischer A, Choi JN, Lacouture ME. Dermatological adverse events from BRAF inhibitors: a growing problem. Curr Oncol Rep. 2013;15:249-259.
7. Lacouture ME, Duvic M, Hauschild A, et al. Analysis of dermato-logic events in vemurafenib-treated patients with melanoma. Oncologist. 2013;18:314-322.
8. Boussemart L, Routier E, Mateus C, et al. Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients. Ann Oncol. 2013;24:1691-1697.
9. Rinderknecht JD, Goldinger SM, Rozati S, Kamarashev J, Kerl K, French LE, Dummer R, Belloni B. RASopathic skin eruptions during vemurafenib therapy. PLoS One. 2013;8:e58721.
10. Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012;367:1694-1703.
11. Anforth RM, Blumetti TC, Kefford RF, et al. Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma. Br J Dermatol. 2012; 167:1153-1160.
12. Rosendahl C, Cameron A, Argenziano G, Zalaudek I, Tschandl P, Kittler H. Dermoscopy of squamous cell carcinoma and keratoacan-thoma. Arch Dermatol. 2012;148:1386-1392.
13. Marghoob AA, Usatine RP, Jaimes N. Dermoscopy for the family physician. Am Fam Physician. 2013;88:441-450.
14. Hall-Jackson CA, Eyers PA, Cohen P, et al. Paradoxical activation of Raf by a novel Raf inhibitor. Chem Biol. 1999;6:559-568.
15. Robert C, Arnault JP, Mateus C. RAF inhibition and induction of cutaneous squamous cell carcinoma. Curr Opin Oncol. 2011;23:177-182.
16. Lacouture M, Chapman PB, Ribas A, et al. Presence of frequent underlying RAS mutations in cutaneous squamous cell carcinomas and keratoacanthomas (cuSCC/KA) that develop in patients during vemurafenib therapy [abstract]. J Clin Oncol. 2011;29(suppl):8520.
17. Su F, Viros A, Milagre C, et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med. 2012;366:207-215.
18. Arnault JP, Mateus C, Escudier B, et al. Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1. Clin Cancer Res. 2012; 18:263-272.
19. Anforth R, Fernandez-Penas P, Long GV. Cutaneous toxicities of RAF inhibitors. Lancet Oncol. 2013;14:e11-e18.
20. Mattei PL, Alora-Palli MB, Kraft S, Lawrence DP, Flaherty KT, Kimball AB. Cutaneous effects of BRAF inhibitor therapy: a case series. Ann Oncol. 2013;24:530-537.
21. Lindelof B, Sigurgeirsson B, Gabel H, Stern RS. Incidence of skin cancer in 5356 patients following organ transplantation. Br J Derma-tol. 2000;143:513-519.
22. Jaimes N, Zalaudek I, Braun RP, Tan BH, Busam KJ, Marghoob AA. Pearls of keratinizing tumors. Arch Dermatol. 2012;148:976.
23. Blessing K, al Nafussi A, Gordon PM. The regressing keratoacan-thoma. Histopathology. 1994;24:381-384.